(Q28305237)

https://api.crossref.org/works/10.1592%2FPHCO.29.1.64

Focus on prolactin as a metabolic hormone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.64

Prolactin and the prolactin receptor: new targets of an old hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.64

Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.64

Plasma prolactin and central D2 receptor occupancy in antipsychotic drug-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.64

Medication-induced hyperprolactinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.64

Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.64

Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.64

Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.64

Bone mineral density in male schizophrenia patients: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.64

Osteoporosis in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.64

Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.64

A study of serum prolactin levels in schizophrenia: comparison of males and females

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.64

The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.64

Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.64

The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.64

Plasma concentrations of estradiol in women suffering from schizophrenia treated with conventional versus atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.64

Improvement In Indices Of Health Status In Outpatients With Schizophrenia Switched To Ziprasidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.64

Adverse effects of atypical antipsychotics : differential risk and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.64

Psychotropic practice patterns for youth: a 10-year perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.64

Psychotherapeutic medication prevalence in Medicaid-insured preschoolers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.64

Olanzapine vs. other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Out-patient Health Outcomes study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.64

Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.64

Sexuality and schizophrenia: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.64

What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.64

Estradiol levels in psychotic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.64

Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.64

Risk of hip fracture in patients with a history of schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.64

Plasma Prolactin Levels and Subsequent Risk of Breast Cancer in Postmenopausal Women

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.64

Prolactin and breast cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.64

Dopamine antagonists and the development of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.64

Are chronic psychiatric patients at increased risk for developing breast cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.64

Atypical antipsychotics and pituitary tumors: a pharmacovigilance study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.64

Physical health monitoring of patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.64

Hyperprolactinemia and amenorrhea associated with olanzapine normalized after addition of aripiprazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.64

Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.64

Dopamine agonist therapy for hyperprolactinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.64

Hyperprolactinemia and bone mineral density: the potential impact of antipsychotic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.64

Osteoporosis, schizophrenia and antipsychotics: the need for a comprehensive multifactorial evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.64

Decreased bone mineral density in male schizophrenia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.64